

Title (en)

COMPOSITION AND VACCINE FOR TREATING PROSTATE CANCER

Title (de)

ZUSAMMENSETZUNG UND IMPFSTOFF ZUR BEHANDLUNG VON PROSTATAKREBS

Title (fr)

COMPOSITION ET VACCIN POUR LE TRAITEMENT DU CANCER DE LA PROSTATE

Publication

EP 3035954 A1 20160629 (EN)

Application

EP 14755332 A 20140821

Priority

- EP 2013002516 W 20130821
- EP 2013002515 W 20130821
- EP 2014002297 W 20140821
- EP 14755332 A 20140821

IPC 8 full level

A61K 39/00 (2006.01)

CPC (source: EP US)

A61K 39/0011 (2013.01 - EP US); **A61K 39/00117** (2018.08 - EP US); **A61K 39/001193** (2018.08 - EP US); **A61K 39/001194** (2018.08 - EP US); **A61K 39/001195** (2018.08 - EP US); **A61K 2039/53** (2013.01 - EP)

Citation (examination)

- JOHNSON L E ET AL: "Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 3, 16 January 2006 (2006-01-16), pages 293 - 303, XP028010445, ISSN: 0264-410X, [retrieved on 20060116], DOI: 10.1016/J.VACCINE.2005.07.074
- DREICER R ET AL: "MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 27, no. 4, 18 October 2008 (2008-10-18), pages 379 - 386, XP019673837, ISSN: 1573-0646
- See also references of WO 2015024664A1

Cited by

EP4035659A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 3035954 A1 20160629

DOCDB simple family (application)

EP 14755332 A 20140821